| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYCL1 |
| Uniprot No | P12524 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-364aa |
| 氨基酸序列 | MDYDSYQHYF YDYDCGEDFY RSTAPSEDIW KKFELVPSPP TSPPWGLGPG AGDPAPGIGP PEPWPGGCTG DEAESRGHSK GWGRNYASII RRDCMWSGFS ARERLERAVS DRLAPGAPRG NPPKASAAPD CTPSLEAGNP APAAPCPLGE PKTQACSGSE SPSDSENEEI DVVTVEKRQS LGIRKPVTIT VRADPLDPCM KHFHISIHQQ QHNYAARFPP ESCSQEEASE RGPQEEVLER DAAGEKEDEE DEEIVSPPPV ESEAAQSCHP KPVSSDTEDV TKRKNHNFLE RKRRNDLRSR FLALRDQVPT LASCSKAPKV VILSKALEYL QALVGAEKRM ATEKRQLRCR QQQLQKRIAY LTGY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYCL1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "Functional characterization of recombinant MYCL1 in lung cancer progression"
**作者**: Takahashi, K. et al.
**摘要**: 本研究在大肠杆菌中成功表达并纯化了重组MYCL1蛋白，发现其通过调控Wnt/β-catenin通路促进肺癌细胞增殖和迁移，为靶向治疗提供了潜在靶点。
2. **文献名称**: "Structural insights into MYCL1-DNA interaction using recombinant protein crystallography"
**作者**: Miller, R. & Zhang, H.
**摘要**: 通过重组MYCL1蛋白的晶体结构解析，揭示了其DNA结合域的关键氨基酸残基，阐明了MYCL1与靶基因启动子特异性结合的分子机制。
3. **文献名称**: "Recombinant MYCL1 fusion protein enhances CRISPR-mediated transcriptional activation in cellular models"
**作者**: Chen, L. et al.
**摘要**: 开发了MYCL1-dCas9重组融合蛋白，验证其可显著提高基因编辑系统在哺乳动物细胞中的转录激活效率，为基因治疗工具优化提供了新策略。
注：上述文献为示例性内容，实际研究中建议通过PubMed或Web of Science以关键词“MYCL1 recombinant”检索最新论文。若需真实文献，可提供具体研究方向进一步协助筛选。
MYCL1 (MYC proto-oncogene bHLH transcription factor L1), also known as L-MYC, is a member of the MYC family of oncogenic transcription factors, which includes c-MYC and MYCN. It plays a role in regulating cell proliferation, differentiation, apoptosis, and metabolism by forming heterodimers with MAX proteins to bind DNA and modulate target gene expression. MYCL1 is located on chromosome 1p34.3 and is frequently amplified or dysregulated in various cancers, notably small cell lung cancer (SCLC) and neuroblastoma. Unlike c-MYC, MYCL1 exhibits weaker transforming activity but is associated with specific tumorigenic contexts, particularly in hypoxia-sensitive cancers.
Recombinant MYCL1 protein is engineered in vitro for functional studies, enabling researchers to dissect its molecular interactions, DNA-binding properties, and regulatory mechanisms. Produced using expression systems like *E. coli* or mammalian cells, the recombinant protein typically includes affinity tags (e.g., His-tag) for purification. Its applications span cancer biology research—exploring MYCL1’s role in tumor progression, metabolic reprogramming, and therapeutic resistance—as well as drug discovery screens targeting MYC family oncoproteins. Additionally, it serves as an antigen for diagnostic antibody development. Despite challenges in targeting MYC proteins due to their unstructured nature, recombinant MYCL1 remains a critical tool for elucidating oncogenic pathways and identifying indirect therapeutic strategies.
×
